Liminal BioSciences Inc. LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc. > Huge step finally! NR:First Subject Dosed in Phase 1 Multipl

<< Previous

Bullboard Posts

Next >>

Comment by GunnerGon Dec 15, 2020 12:45pm

89 Views

Post# 32109534

RE:Huge step finally! NR:First Subject Dosed in Phase 1 Multipl

This is for anyone other than Stups.

Didn't we already do this when it was called 4050? Is the Alstrom trial in Britain, thought LMNL was talking stage 3 trials, dead?

realstocky wrote:
Liminal BioSciences Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras

2 hours ago

LAVAL, QC , and CAMBRIDGE, England , Dec. 15, 2020 /CNW Telbec/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today announced that the first subject has been dosed in the Company's fezagepras Phase 1 multiple ascending dose clinical trial in healthy volunteers.

The new clinical trial is designed to look at more frequent daily dosing (twice and three times daily) of fezagepras up to 2,400mg for a total of 14 days. The clinical trial is a standard placebo-controlled Phase 1 ascending dose design in healthy volunteers. The clinical trial endpoints will include safety, pharmacokinetics, and exploratory biomarkers related to the mechanism of action of fezagepras. The data from this clinical trial will be used to guide selection of the appropriate dose and dosing frequency of fezagepras for anticipated future clinical trials.

"We are conducting this clinical trial with fezagepras to help define the optimal dosing regimen that we expect to take forward into phase 2 clinical development in patients with idiopathic pulmonary fibrosis (IPF)", said Bruce Pritchard , Chief Executive Officer of Liminal BioSciences.